📰 Programmed Death News
Programmed Death News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Programmed Death. Real-time updates on events, politics, business and more.
November 3, 2023
Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of...
May 4, 2022
BU dental researchers have found that taking down a protein in the tongue could help defeat oral cancer tumors.
February 4, 2022
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 14, 2022, Health Canada has authorized TECENTRIQ® (atezolizumab) as - Click here if this is your press release! - Travel News | eTurboNews | eTN
January 27, 2022
An international research collaboration says it has found evidence pembrolizumab can reverse HIV latency – the ability for the virus to 'hide' inside cells of people living with HIV on antiretroviral therapy
January 27, 2022
(Reuters) - Researchers studying Merck & Co Inc's cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace t...
December 10, 2021
Investegate announcements from F. Hoffmann-La Roche Ltd, New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
October 15, 2021
Investegate announcements from F. Hoffmann-La Roche Ltd, US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
October 15, 2021
-- Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting -- Approval is based on the Phase III IMpower010 study showing adjuvant ... | October 15, 2021
October 15, 2021
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival
May 13, 2021
Immuno-Oncology Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027 7Newswire 13 May 2021, 22:51 GMT+10 The research report titled Immuno-Oncology offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product usage and consumer psyche. This report provides an extensive analysis on market segmentation, strategies for prominent players and market overview. The...